Tags:ChemicalDevelopmentDrugHomeLEDPharmacyResearch
is developing new chemical entities targeting CB2 receptors on microglia, significantly reducing the expression of inflammatory agents resulting in neuronal survival and proliferation.
Location: United States, Cleveland
Member count: 1-10
Total raised: $8.8M

Investors 1

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
22.09.2020Series A$8.8M-NeuroThera...

Mentions in press and media 2

DateTitleDescriptionCategoryAuthorSource
25.09.2020NeuroThera...NeuroTherapia, Inc., a Clevela...USA-finsmes.co...
22.09.2020NeuroThera... CLEVELAND, Sept. 22, 2020 /P...--prnewswire...